Details of the Drug Combination

General Information of Drug Combination (ID: DCGM91U)

• Drug Combination Name: Warfarin + Fondaparinux sodium
• Indication: Heparin-Induced Thrombocytopenia; Status: Phase 1 [1]
• Component Drugs:
  Warfarin (DMJYCVW): Small molecular drug
  Fondaparinux sodium (DMWS3FH): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Warfarin

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Approved	[2]
Deep vein thrombosis	BD71	Approved	[3]
Pulmonary hypertension	BB01	Approved	[3]
Thrombosis	DB61-GB90	Application submitted	[4]
Intracranial embolism	8B22.1	Investigative	[3]
Venous thromboembolism	BD72	Investigative	[3]

Warfarin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Vitamin K epoxide reductase complex 1 (VKORC1)	TTEUC8H	VKOR1_HUMAN	Inhibitor	[12]

Warfarin Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[13]

Warfarin Interacts with 8 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[14]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[15]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[11]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Metabolism	[16]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Metabolism	[17]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[18]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[19]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[15]

Warfarin Interacts with 52 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Decreases Expression	[20]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Increases Response To Substance	[21]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Affects Response To Substance	[22]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Affects Response To Substance	[23]
Cytochrome P450 2C18 (CYP2C18)	OTY687L9	CP2CI_HUMAN	Affects Response To Substance	[22]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3)	OTOM3BUH	SO1B3_HUMAN	Affects Response To Substance	[24]
Cytochrome P450 4F2 (CYP4F2)	OTKILAER	CP4F2_HUMAN	Increases Response To Substance	[25]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Decreases Activity	[26]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Decreases Expression	[20]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Decreases Expression	[27]
Antithrombin-III (SERPINC1)	OTDFATG0	ANT3_HUMAN	Increases Expression	[28]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Decreases Expression	[29]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Affects Binding	[30]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Degradation	[31]
Coagulation factor VII (F7)	OTGNJ97M	FA7_HUMAN	Decreases Expression	[27]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Expression	[8]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[8]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP)	OT0DH40W	AL5AP_HUMAN	Increases Expression	[32]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[8]
Arylsulfatase L (ARSL)	OTF1VTCR	ARSL_HUMAN	Decreases Activity	[33]
Growth arrest-specific protein 6 (GAS6)	OTPOPUUE	GAS6_HUMAN	Decreases Carboxylation	[8]
Endomucin (EMCN)	OTS03CZC	MUCEN_HUMAN	Decreases Expression	[8]
Serine protease 53 (PRSS53)	OT3HUUI3	PRS53_HUMAN	Affects Response To Substance	[34]
Aspartyl/asparaginyl beta-hydroxylase (ASPH)	OT3KGDEE	ASPH_HUMAN	Affects Response To Substance	[35]
Ephrin type-A receptor 7 (EPHA7)	OT3VC211	EPHA7_HUMAN	Affects Response To Substance	[36]
Myosin-6 (MYH6)	OT3YNCH1	MYH6_HUMAN	Affects Response To Substance	[37]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Affects Response To Substance	[38]
Epoxide hydrolase 1 (EPHX1)	OTBKWQER	HYEP_HUMAN	Increases Response To Substance	[39]
Coagulation factor V (F5)	OTDMZ3LT	FA5_HUMAN	Affects Response To Substance	[22]
Solute carrier family 15 member 2 (SLC15A2)	OTDV7YES	S15A2_HUMAN	Affects Response To Substance	[24]
Vitamin K-dependent gamma-carboxylase (GGCX)	OTE0FNAP	VKGC_HUMAN	Decreases Response To Substance	[7]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Affects Response To Substance	[40]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Affects Response To Substance	[41]
E3 ubiquitin-protein ligase NEDD4 (NEDD4)	OTFPXLXT	NEDD4_HUMAN	Affects Response To Substance	[35]
Vitamin K-dependent protein C (PROC)	OTGVH484	PROC_HUMAN	Increases Response To Substance	[39]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Affects Response To Substance	[42]
Prolow-density lipoprotein receptor-related protein 1 (LRP1)	OTHTEH4G	LRP1_HUMAN	Affects Response To Substance	[38]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Increases Response To Substance	[8]
Transcription factor GATA-6 (GATA6)	OTO2BC0F	GATA6_HUMAN	Affects Response To Substance	[43]
Transcription factor GATA-4 (GATA4)	OTQHWAZG	GATA4_HUMAN	Affects Response To Substance	[43]
Fibroblast growth factor 5 (FGF5)	OTQXGHBY	FGF5_HUMAN	Affects Response To Substance	[44]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Affects Response To Substance	[22]
Calumenin (CALU)	OTSYQN71	CALU_HUMAN	Affects Response To Substance	[45]
Coagulation factor IX (F9)	OTT0CX3Q	FA9_HUMAN	Increases Response To Substance	[46]
Heme A synthase COX15 (COX15)	OTUIYHIW	COX15_HUMAN	Affects Response To Substance	[44]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Affects Response To Substance	[47]
Folylpolyglutamate synthase, mitochondrial (FPGS)	OTW3F1ZE	FOLC_HUMAN	Affects Response To Substance	[48]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Affects Response To Substance	[49]
Phospholipase DDHD1 (DDHD1)	OTWTHOWK	DDHD1_HUMAN	Affects Response To Substance	[35]
Vitamin K-dependent protein S (PROS1)	OTXQWNOI	PROS_HUMAN	Affects Response To Substance	[22]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Affects Response To Substance	[50]
Alpha-1-acid glycoprotein 1 (ORM1)	OTZKSBRE	A1AG1_HUMAN	Increases Response To Substance	[39]

Indication(s) of Fondaparinux sodium

Disease Entry	ICD 11	Status	REF
Deep vein thrombosis	BD71	Approved	[5]
Myocardial infarction	BA41-BA43	Approved	[5]
Venous thrombosis	BA43	Approved	[6]

Fondaparinux sodium Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[51]

References

• [1] ClinicalTrials.gov (NCT00673439) Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6853).
• [3] Warfarin FDA Label
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Fondaparinux sodium FDA Label
• [6] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [7] The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost. 2006 May;95(5):782-7.
• [8] Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res. 2015 Sep 15;75(18):3699-705. doi: 10.1158/0008-5472.CAN-14-2887-T. Epub 2015 Jul 23.
• [9] Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves. Int J Cardiol. 2017 Jun 1;236:393-397. doi: 10.1016/j.ijcard.2017.02.103. Epub 2017 Feb 24.
• [10] Association between VEGFA gene polymorphisms and bleeding complications in patients maintaining therapeutic international normalized ratio. Pharmacogenomics. 2019 Jun;20(9):659-667. doi: 10.2217/pgs-2019-0005. Epub 2019 May 8.
• [11] Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul;22(7):1239-45.
• [12] [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
• [13] Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
• [14] Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
• [15] Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
• [16] Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
• [17] Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
• [18] Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
• [19] Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
• [20] Warfarin calcifies human aortic valve interstitial cells at high-phosphate conditions via pregnane X receptor. J Bone Miner Metab. 2019 Nov;37(6):944-956. doi: 10.1007/s00774-019-01001-3. Epub 2019 Apr 8.
• [21] Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59. Drug Metab Dispos. 2015 Aug;43(8):1246-9. doi: 10.1124/dmd.115.063412. Epub 2015 May 20.
• [22] Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics. 2009 Oct;19(10):800-12. doi: 10.1097/FPC.0b013e3283317ab5.
• [23] Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. J Thromb Haemost. 2021 Dec;19(12):2957-2973. doi: 10.1111/jth.15494. Epub 2021 Sep 29.
• [24] Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
• [25] CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 Apr 15;111(8):4106-12. doi: 10.1182/blood-2007-11-122010. Epub 2008 Feb 4.
• [26] Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 2008 Jul;36(7):1322-31.
• [27] Interaction between fenofibrate and warfarin. Ann Pharmacother. 1998 Jul-Aug;32(7-8):765-8. doi: 10.1345/aph.17310.
• [28] Venous thrombosis, heparin-induced antithrombin III deficiency, and factor VIII. Lancet. 1977 Dec 10;2(8050):1231-2.
• [29] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [30] The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
• [31] P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15065-70. doi: 10.1073/pnas.2436329100. Epub 2003 Nov 21.
• [32] Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A. 2006 May 23;103(21):8161-6. doi: 10.1073/pnas.0602414103. Epub 2006 May 12.
• [33] A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell. 1995 Apr 7;81(1):15-25. doi: 10.1016/0092-8674(95)90367-4.
• [34] Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol. 2011 Nov;67(11):1119-30. doi: 10.1007/s00228-011-1060-1. Epub 2011 May 18.
• [35] Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016 Aug;17(13):1425-39. doi: 10.2217/pgs-2016-0061. Epub 2016 Aug 4.
• [36] Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. JAMA. 2018 Oct 23;320(16):1670-1677. doi: 10.1001/jama.2018.14955.
• [37] Association of the MYH6 Gene Polymorphism with the Risk of Atrial Fibrillation and Warfarin Anticoagulation Therapy. Genet Test Mol Biomarkers. 2021 Sep;25(9):590-599. doi: 10.1089/gtmb.2021.0025. Epub 2021 Sep 9.
• [38] LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes. J Cardiovasc Pharmacol. 2020 Jul;76(1):71-76. doi: 10.1097/FJC.0000000000000834.
• [39] Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther. 2007 Aug;322(2):427-34. doi: 10.1124/jpet.106.117952. Epub 2007 May 11.
• [40] Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population. Mol Diagn Ther. 2014 Feb;18(1):73-83. doi: 10.1007/s40291-013-0055-2.
• [41] Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011 Mar;21(3):130-5. doi: 10.1097/FPC.0b013e3283436b86.
• [42] APOB gene polymorphisms may affect the risk of minor or minimal bleeding complications in patients on warfarin maintaining therapeutic INR. Eur J Hum Genet. 2019 Oct;27(10):1542-1549. doi: 10.1038/s41431-019-0450-1. Epub 2019 Jun 11.
• [43] Genetic variations in the transcription factors GATA4 and GATA6 and bleeding complications in patients receiving warfarin therapy. Drug Des Devel Ther. 2019 May 17;13:1717-1727. doi: 10.2147/DDDT.S198018. eCollection 2019.
• [44] Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array. Pharmacogenomics. 2017 Jul;18(11):1059-1073. doi: 10.2217/pgs-2017-0046. Epub 2017 Jul 7.
• [45] Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics. 2016 Nov;26(11):510-516. doi: 10.1097/FPC.0000000000000244.
• [46] Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations. Ann Hematol. 2018 Jun;97(6):1061-1069. doi: 10.1007/s00277-018-3264-2. Epub 2018 Feb 15.
• [47] Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. Eur J Clin Pharmacol. 2016 Nov;72(11):1327-1334. doi: 10.1007/s00228-016-2098-x. Epub 2016 Aug 4.
• [48] Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood. 2014 Oct 2;124(14):2298-305. doi: 10.1182/blood-2014-04-568436. Epub 2014 Jul 30.
• [49] Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study. Thromb Res. 2014 Dec;134(6):1359-62. doi: 10.1016/j.thromres.2014.09.017. Epub 2014 Sep 20.
• [50] Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur J Clin Pharmacol. 2015 Oct;71(10):1229-36. doi: 10.1007/s00228-015-1915-y. Epub 2015 Aug 11.
• [51] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.